ID
42532
Beschreibung
Study ID: 105874 Clinical Study ID: 105874 Study Title: Bridging Safety & Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine RTS,S/AS01E (0.5 mL Dose) to RTS,S/AS02D (0.5 mL Dose) Administered IM According to a 0, 1, 2-Month Schedule in Gabonese Children Aged 18 Months to 4 Years Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00307021 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049 Trade Name: N/A Study Indication: Malaria ODM derived from https://clinicaltrials.gov/ct2/show/NCT00307021. A Phase II randomized, double-blind bridging study of the safety and immunogenicity of GlaxoSmithKline Plasmodium falciparum malaria vaccine RTS,S/AS01E (0.5 mL dose) to RTS,S/AS02D (0.5 mL dose) administered IM according to a 0, 1, 2- month vaccination schedule in children aged 18 months to 4 years living in Gabon. Clinical Visits: This study has a total of 7 visits. Visit 1 = Screening, Visits 2-6 are during the double-blind phase (Month 0-3) and Visit 7 is during the single-blind phase (Month 4-14). Vaccine administration takes place during visits 2, 4, and 5 (Visit 2 = Dose 1; Visit 4 = Dose 2; Visit 5 = Dose 3). Field-worker Visits: During the double-blind phase, clinical visits are accompanied by daily field-worker visits subsequent to each vaccine administration visit. Additional field-worker visits also take place during months 4 to 13 of the single-blind phase. The check for study continuation should be performed and documented at all clinical visits subsequent to the screening visit (i.e., visits 2, 3, 4, 5, 6, and 7). Reasons for withdrawal only need to be specified if the subject has not returned. Note that informed consent has to be obtained prior to any study procedure.
Link
https://clinicaltrials.gov/ct2/show/NCT00307021
Stichworte
Versionen (1)
- 24.08.21 24.08.21 -
Rechteinhaber
GlaxoSmithKline
Hochgeladen am
24. August 2021
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Safety & Immunogenicity of two GSK Biologicals' Candidate Malaria Vaccines in young children, NCT00307021
Check for Study Continuation
- StudyEvent: ODM
Beschreibung
Check for Study Continuation
Alias
- UMLS CUI-1
- C0805733
- UMLS CUI-2
- C0008976
Beschreibung
If yes, please complete the forms for this visit. If no, please complete this form and skip the other forms for this visit.
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0545082
- UMLS CUI [1,2]
- C0805733
- UMLS CUI [1,3]
- C0008976
Beschreibung
Only possible to tick at visits 3, 4, 5, 6, or 7. For visit 2 OR if withdrawal reason and justification are not equal to the previous visit, please fill in the following question in this form.
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0457454
- UMLS CUI [1,2]
- C0008976
- UMLS CUI [1,3]
- C0566251
- UMLS CUI [1,4]
- C0205225
- UMLS CUI [1,5]
- C2127115
- UMLS CUI [2,1]
- C0457454
- UMLS CUI [2,2]
- C0008976
- UMLS CUI [2,3]
- C0679006
- UMLS CUI [2,4]
- C2127115
Beschreibung
Discontinuation clinical trial primary reason and justification
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0457454
- UMLS CUI [1,2]
- C0008976
- UMLS CUI [1,3]
- C0566251
- UMLS CUI [1,4]
- C0205225
Beschreibung
If serious adverse event [SAE], please also complete the SAE form.
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C1519255
- UMLS CUI [1,2]
- C0237753
- UMLS CUI [1,3]
- C1521902
Beschreibung
If non-serious adverse event [AEX], please also complete the non-serious adverse event section.
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C1518404
- UMLS CUI [1,2]
- C0237753
- UMLS CUI [1,3]
- C1521902
Beschreibung
Discontinuation clinical trial primary reason to specify | consent withdrawal | protocol violation
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0457454
- UMLS CUI [1,2]
- C0008976
- UMLS CUI [1,3]
- C0566251
- UMLS CUI [1,4]
- C0205225
- UMLS CUI [1,5]
- C1521902
- UMLS CUI [2]
- C1707492
- UMLS CUI [3]
- C1709750
Beschreibung
Discontinuation clinical trial decision maker
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0457454
- UMLS CUI [1,2]
- C0008976
- UMLS CUI [1,3]
- C0679006
Ähnliche Modelle
Check for Study Continuation
- StudyEvent: ODM
C0008976 (UMLS CUI-2)
C0805733 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
C0008976 (UMLS CUI [1,2])
C0566251 (UMLS CUI [1,3])
C0205225 (UMLS CUI [1,4])
C2127115 (UMLS CUI [1,5])
C0457454 (UMLS CUI [2,1])
C0008976 (UMLS CUI [2,2])
C0679006 (UMLS CUI [2,3])
C2127115 (UMLS CUI [2,4])
C0008976 (UMLS CUI [1,2])
C0566251 (UMLS CUI [1,3])
C0205225 (UMLS CUI [1,4])
C0237753 (UMLS CUI [1,2])
C1521902 (UMLS CUI [1,3])
C0237753 (UMLS CUI [1,2])
C1521902 (UMLS CUI [1,3])
C0008976 (UMLS CUI [1,2])
C0566251 (UMLS CUI [1,3])
C0205225 (UMLS CUI [1,4])
C1521902 (UMLS CUI [1,5])
C1707492 (UMLS CUI [2])
C1709750 (UMLS CUI [3])
C0008976 (UMLS CUI [1,2])
C0679006 (UMLS CUI [1,3])